Clinical
July 28, 2026
Promoting Resilience in Neurodegenerative Diseases
Novel small-molecule therapies targeting the root causes of degeneration to protect synapses and restore function.
Our Mission
Harnessing fundamental biology to create novel therapeutic solutions.
PharmatrophiX is a clinical-stage biopharmaceutical company focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. We are advancing a pipeline of small-molecule drugs targeting p75 as well as the TrkB and TrkC receptors designed to prevent fundamental neurodegenerative mechanisms and to promote synaptic resilience.
About UsOur Mission
Harnessing fundamental biology to create novel therapeutic solutions.
PharmatrophiX is a clinical-stage biopharmaceutical company focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. We are advancing a pipeline of small-molecule drugs targeting p75 as well as the TrkB and TrkC receptors designed to prevent fundamental neurodegenerative mechanisms and to promote synaptic resilience.
About UsOur Approach
Neurodegenerative
Challenges Today
Over 7 million Americans are living with Alzheimer’s disease today and with a new case diagnosed every 33 seconds, by 2050, this number is projected to rise to nearly 13 million Americans. According to the Alzheimer’s Association, health and long-term care costs for people living with Alzheimer’s, Parkinson’s and other dementias in the U.S. are expected to reach $409 billion in 2026 and $1.1 trillion by 2050.
7M+
Living with Alzheimer’s
Americans impacted today, projected to reach nearly 13M by 2050.
33s
New case diagnosed
A new Alzheimer’s case is diagnosed every 33 seconds.
$1.1T
Projected care cost
Annual U.S. spend on dementia care by 2050, up from $384B in 2025.
Lead Asset
LM11A-31
Completed Phase 2a Clinical Trial
LM11A-31 is a first-in-class small molecule targeting the p75 neurotrophin receptor. It shifts signaling away from degeneration and toward synaptic protection, offering hope for patients and families.
- Supports synaptic integrity and prevents their degeneration across a wide range of pathological mechanisms
- Reduces the accumulation of pathological-toxic forms of tau and inhibits the spread of those forms through the brain
- Restores the compromised signaling of synapses in multiple neurodegenerative models
Mechanism of Action
LM11A-31 modulates p75NTR signaling to shift from degeneration toward neuronal protection and synaptic repair.
Explore
Discover
PharmatrophiX
Clinical
July 13, 2026
Indiana University and PharmatrophiX Present Findings on Performance of Oral Therapeutic, LM11A-31, to Reduce Decline of Brain Functional-Network Connectivity in Alzheimer’s Disease
New findings presented at featured research session (FRS) during the Alzheimer’s Association International Conference demonstrate statistically significant slowing of decline…
Read More
Clinical
May 14, 2026
PharmatrophiX Selected for Landmark UCSF-led platform trial in rare neurodegenerative disease; Unveils New Data at Tau Global Conference
PharmatrophiX unveiled preclinical data at the Global Tau Conference further supporting evidence that LM11A-31 is a multi-action shield for the…
Read More